{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:23:28Z","timestamp":1793334208481,"version":"4.5.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD), emerges as major cause of morbidity and mortality globally, with chronic patients facing increased risk. Guidelines on MASLD management in primary care (PC) are limited. This study aimed to develop and evaluate a clinical care pathway for use in PC to improve MASLD screening and management, including early detection, communication and treatment, in three European countries (Greece, Spain, the Netherlands).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>An international multidisciplinary panel of experts oversaw pathway development, which was designed as a two-step algorithm with defined and sequenced tasks. To evaluate algorithm implementation, a controlled pilot study was conducted. Patients at risk of MASLD were assigned to general practitioners (GPs) trained in algorithm implementation (active group) or usual care (control group) and followed for 4\u20138\u2009weeks. Primary outcomes were the number of patients screened for MASLD, managed in PC and referred to specialists.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In this algorithm, patients with metabolic or liver dysfunction, confirmed MASLD or cardiovascular disease are screened with FIB-4 and classified as having risk of low-level (FIB-4\u2009&amp;lt;\u20091.3), intermediate-level (1.3\u2009\u2264\u2009FIB-4\u2009&amp;lt;\u20092.67) or high-level MASLD (FIB-4\u2009\u2265\u20092.67). The algorithm provides evidence-based tools to support GPs manage patients with risk of low-level MASLD in PC, coordinate linkage of patients with risk of high-level MASLD to specialists and refer patients with risk of intermediate-level MASLD for elastography (low-risk if &amp;lt;7.9\u2009kPa or intermediate\/high-risk if \u22657.9\u2009kPa). During pilot evaluation, <jats:italic>N<\/jats:italic>\u2009=\u200937 participants were recruited in Spain (54.1% women, median age: 63\u2009years). Significantly higher rates of patients in the active group (<jats:italic>n<\/jats:italic>\u2009=\u200917) than the control group (<jats:italic>n<\/jats:italic>\u2009=\u200920) were screened with FIB-4 (94.1% vs. 5.5%, <jats:italic>p<\/jats:italic>\u2009=\u20090.004). Patients in the active group received significantly more frequently a PC intervention for weight loss (70.6% vs. 10.0%, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001), alcohol regulation (52.9% vs. 0%, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001) and smoking cessation (29.4% vs. 0%, <jats:italic>p<\/jats:italic>\u2009=\u20090.005). In Greece no algorithm implementation was observed in either the active or control group, while the evaluation was not conducted in the Netherlands for logistic reasons.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study provides evidence on the development and implementation of a new PC algorithm for MASLD screening and management. Variations among participating settings in algorithm implementation are indicative of context-specific particularities. Further research is necessary for integrating such pathways in tailored interventions to tackle this emerging public health issue.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1383112","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T04:34:01Z","timestamp":1732163641000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Development and pilot evaluation of an evidence-based algorithm for MASLD (formerly NAFLD) management in primary care in Europe"],"prefix":"10.3389","volume":"11","author":[{"given":"Marilena","family":"Anastasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Papadakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irini N.","family":"Gergianaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loucas","family":"Papastamatiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eftychios","family":"Aligizakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikoleta","family":"Grillaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Boutzoukaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nektarios","family":"Sivaropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foteini","family":"Anastasiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Mendive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"de Juan-Asenjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Hern\u00e1ndez-Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Mart\u00ednez-Escud\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Garcia-Retortillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ger","family":"Koek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leen","family":"Heyens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Muris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos D.","family":"Lionis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jhep.2010.04.008","article-title":"A position statement on NAFLD\/NASH based on the EASL 2009 special conference","volume":"53","author":"Ratziu","year":"2010","journal-title":"J Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1053\/j.gastro.2011.06.061","article-title":"Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States","volume":"141","author":"Charlton","year":"2011","journal-title":"Gastroenterology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1185\/03007995.2010.506375","article-title":"Population-based risk factors and resource utilization for HCC: US perspective","volume":"26","author":"Sanyal","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/imj.13667","article-title":"Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis","volume":"48","author":"Patel","year":"2018","journal-title":"Intern Med J"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1136\/flgastro-2013-100404","article-title":"Non-alcoholic fatty liver disease: a practical approach to treatment","volume":"5","author":"Dyson","year":"2014","journal-title":"Frontline Gastroenterol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/liv.13302","article-title":"Therapies in non-alcoholic steatohepatitis (NASH)","volume":"37","author":"Oseini","year":"2017","journal-title":"Liver Int"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jhep.2019.03.033","article-title":"Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease","volume":"71","author":"Srivastava","year":"2019","journal-title":"J Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"k2734","DOI":"10.1136\/bmj.k2734","article-title":"Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults","volume":"362","author":"Byrne","year":"2018","journal-title":"BMJ"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/cld.885","article-title":"The burden and clinical care pathways of nonalcoholic steatohepatitis in the Middle East","volume":"14","author":"Hasan","year":"2019","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12913-015-0854-8","article-title":"Effectiveness of chronic care models: opportunities for improving healthcare practice and health outcomes: a systematic review","volume":"15","author":"Davy","year":"2015","journal-title":"BMC Health Serv Res"},{"key":"ref13","year":"2022"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1016\/S0140-6736(12)60480-2","article-title":"Effectiveness of quality improvement strategies on the management of diabetes: a systematic review and meta-analysis","volume":"379","author":"Tricco","year":"2012","journal-title":"Lancet"},{"key":"ref15","volume-title":"The RAND\/UCLA appropriateness method user\u2019s manual","author":"Fitch","year":"2001"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1034626","DOI":"10.3389\/fmed.2023.1034626","article-title":"Development and implementation of a continuing medical education program on non-alcoholic fatty liver disease for primary care practitioners in Europe","volume":"10","author":"Papadakis","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL\u2013EASD\u2013EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"ref18","year":"2016"},{"key":"ref19","year":"2022"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"5803","DOI":"10.3748\/wjg.v27.i35.5803","article-title":"Screening for nonalcoholic fatty liver disease-when, who and how?","volume":"27","author":"Dietrich","year":"2021","journal-title":"World J Gastroenterol"},{"key":"ref21","first-page":"357","article-title":"Screening for nonalcoholic fatty liver disease in the primary care clinic","volume":"15","author":"Pandyarajan","year":"2019","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e000904","DOI":"10.1136\/bmjdrc-2019-000904","article-title":"Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications","volume":"8","author":"Ciardullo","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"289","DOI":"10.15403\/jgld-420","article-title":"Step layered combination of noninvasive fibrosis models improves diagnostic accuracy of advanced fibrosis in nonalcoholic fatty liver disease","volume":"28","author":"Yang","year":"2019","journal-title":"J Gastrointestin Liver Dis"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1186\/s12913-022-07808-7","article-title":"Implementing the right care in the right place at the right time for non-alcoholic fatty liver disease (NAFLD-RRR study): a study protocol for a community care pathway for people with type 2 diabetes","volume":"22","author":"Gracen","year":"2022","journal-title":"BMC Health Serv Res"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1007\/s10620-016-4143-0","article-title":"Global epidemiology of nonalcoholic fatty liver disease and perspectives on US minority populations","volume":"61","author":"Sherif","year":"2016","journal-title":"Dig Dis Sci"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.diabres.2018.02.023","article-title":"IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045","volume":"138","author":"Cho","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.15761\/GHE.1000208","article-title":"Epidemiology and severity of nonalcoholic fatty liver disease in Greek tertiary liver centres","volume":"5","author":"Savvidou","year":"2020","journal-title":"Gastroenterol Hepatol Endosc"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1093\/eurpub\/ckab165.202","article-title":"Heath literacy, illness perception and NAFLD\/NASH awareness in primary care patients in Crete, Greece","volume":"31","author":"Gergianaki","year":"2021","journal-title":"Eur J Pub Health"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1016\/j.cgh.2021.12.034","article-title":"Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population","volume":"20","author":"Graupera","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(21)01701-3","article-title":"The EASL-lancet liver commission: protecting the next generation of Europeans against liver disease complications and premature mortality","volume":"399","author":"Karlsen","year":"2022","journal-title":"Lancet"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1017\/S1463423619000446","article-title":"Integrated people-centred primary health care in Greece: unravelling Ariadne's thread","volume":"20","author":"Lionis","year":"2019","journal-title":"Prim Health Care Res Dev"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e743","DOI":"10.3399\/bjgp18X699377","article-title":"GPs' experiences and perceptions of early detection of liver disease: a qualitative study in primary care","volume":"68","author":"Standing","year":"2018","journal-title":"Br J Gen Pract"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jhep.2019.08.027","article-title":"A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe","volume":"72","author":"Lazarus","year":"2020","journal-title":"J Hepatol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/joim.12972","article-title":"We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade","volume":"286","author":"Lazarus","year":"2019","journal-title":"J Intern Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41575-021-00477-7","article-title":"Defining comprehensive models of care for NAFLD","volume":"18","author":"Lazarus","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: a consensus statement","volume":"19","author":"Lazarus","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S2468-1253(18)30077-3","article-title":"Non-alcoholic fatty liver disease and the interface between primary and secondary care","volume":"3","author":"Tsochatzis","year":"2018","journal-title":"Lancet Gast Hep"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1186\/s12913-021-06678-9","article-title":"The effectiveness of primary health care reforms in Greece towards achieving universal health coverage: a scoping review","volume":"21","author":"Myloneros","year":"2021","journal-title":"BMC Health Serv Res"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1383112\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T04:34:04Z","timestamp":1732163644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1383112\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":38,"alternative-id":["10.3389\/fmed.2024.1383112"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1383112","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,21]]},"article-number":"1383112"}}